Imagion Biosystems has released “Preliminary Report and Appendix 4E for the year ended 31 December 2018.
View Appendix 4E and Preliminary Report.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)